The programme offers a single gene confirmatory test for individuals with a family history of ALSP. Credit: National Cancer Institute on Unsplash.

Vigil Neuroscience has introduced a new programme, referred to as ALSPAware, to offer no-cost genetic testing and counselling to diagnose adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

The CSF1R gene mutation causes ALSP – a rare, inherited, autosomal dominant neurological disease with high penetrance.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

InformedDNA coordinates the programme, which provides services to US residents aged 18 years and above.

The programme, which is designed with a focus on both patients and healthcare providers, offers a confirmatory test for a single gene for individuals with a family history of ALSP.

Furthermore, it offers a custom gene panel to physicians to diagnose adult-onset neurological diseases.

See Also:

Trained genetic counsellors will extend their support in testing and discussing results.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vigil president and CEO Dr Ivana Magovčević-Liebisch said: “Limited access to genetic testing and appropriate counselling has led to diagnostic challenges affecting not only those living with ALSP but also the healthcare providers hoping to treat the disease.

“Only about one-third of people living with ALSP receive a correct diagnosis when symptoms first appear, resulting in a delay that can significantly increase the burden of this devastating genetic condition.”

“We believe that everyone deserves access to the services necessary to make the diagnostic journey as efficient and convenient as possible and we are proud to be taking this important step forward in supporting the ALSP community.”

Vigil is engaged in the development of treatments for both rare and common neurodegenerative diseases through the restoration of microglia vigilance.